This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
The study concluded that there was no evidence for an increased risk of cardiovascular outcomes with tofacitinib in patients with RA treated in the real-world setting; however, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
Forest plot of propensity score fine stratification weighted HRs and corresponding 95% CIs for composite cardiovascular outcomes when comparing tofacitinib with tumour necrosis factor inhibitors in patients with rheumatoid arthritis in RWE cohort (top panel) and RCT-duplicate cohort (bottom panel). RCT, randomised controlled trial; RWE, real-world evidence.
Image adapted from Khosrow-Khavar F, et al. 2022.
All estimates were pooled using fixed effects models with inverse variance weighting.
†Primary outcome: Composite CV outcome of hospitalization for MI or stroke.
‡TNFi: infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab
§Patients from Medicare were ≥65 years old.
║CV risk factors include history of smoking, hypertension, dyslipidemia, diabetes mellitus, IHD or family history of IHD.
Table adapted and graph created from Khosrow-Khavar F, et al. 2022.
†Primary outcome: Composite CV outcome of hospitalization for MI or stroke.
TNFi: infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab. §Patients ≥18 years old (≥65 in Medicare)
Table adapted and graph created from Khosrow-Khavar F, et al. 2022.
†TNFi: infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab.
Patients ≥18 years old (≥65 in Medicare), pooled from Optum, MarketScan, and Medicare US claim databases.
Table adapted and graph created from Khosrow-Khavar F, et al. 2022.
Learn more about STAR-RA Malignancy Risk Study Design
Learn more about the ORAL Surveillance trial.
bDMARD=biologic disease-modifying antirheumatic drug; CI=confidence interval; CV=cardiovascular; CVD=cardiovascular disease; HR=hazard ratio; MI=myocardial infarction; PS=propensity score; RWE=real-world evidence; TNFi=tumor necrosis factor inhibitor
Additional Prescribing Information:
Enbrel (etanercept): https://www.pfizerpiindex.co.uk/enbrel
Inflectra (infliximab): https://www.pfizerpiindex.co.uk/inflectra
References
Prof. Ernest Choy discusses the rationale for XELJANZ (tofacitinib citrate) in RA, the significance of the JAK pathway, JAK selectivity in clinical practice, and efficacy data and the safety profile for JAK inhibitors.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021